Meeting
2021 Gastrointestinal Cancers Symposium
Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study.
Authors
Josep Tabernero
Vall d’Hebron University Hospital and Institute of Oncology (VIHO), Barcelona, Spain
Josep Tabernero , Kohei Shitara , Aziz Zaanan , Toshihiko Doi , Sylvie Lorenzen , Eric Van Cutsem , Lorenzo Fornaro , Daniel V.T. Catenacci , Ronan Fougeray , Shanti Ricardo Moreno Vera , Pablo Azcue , Hendrik-Tobias Arkenau , MARIA ALSINA , David H. Ilson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02500043
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 229)
DOI
10.1200/JCO.2021.39.3_suppl.229
Abstract #
229
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
First Author: Jordyn Kreutzfeldt
Poster
2019 ASCO Annual Meeting
Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).
First Author: Maria Alsina
Poster
2019 ASCO Annual Meeting
Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.
First Author: Kohei Shitara
Poster
2019 ASCO Annual Meeting
Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.
First Author: Wasat Mansoor